Wednesday - April 2, 2025
Experimental Gene-Silencing Drug Produces Long-Duration Reduction in Lipoprotein(a), an Important Heart Disease Risk Factor
April 01, 2025
CLEVELAND, Ohio, April 1 -- The Cleveland Clinic issued the following news release on March 30, 2025:

* * *

Experimental Gene-Silencing Drug Produces Long-Duration Reduction in Lipoprotein(a), an Important Heart Disease Risk Factor

Single and double dosing showed significant reductions in the genetically inherited lipoprotein

CLEVELAND: Findings from a Phase 2 clinical trial reported by a Cleveland Clinic physician show a single dose of an expe . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products